Global News Post Fastest Global News Portal
Related Articles
Novo Nordisk CEO Lars Jorgensen testifies ahead of a Senate Health, Education, Labor, and Pensions Committee listening to on U.S. costs for the burden loss medicine Ozempic and Wegovy, on Capitol Hill in Washington, U.S., September 24, 2024.
Piroschka Van De Wouw | Reuters
Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down, the Wegovy-maker stated Friday, bringing up fresh marketplace demanding situations.
The Danish pharmaceutical large stated Fruergaard Jørgensen would stay in his submit “for a period to support a smooth transition to new leadership.” It added that the seek for a substitute used to be ongoing and a press release can be made in the end.
Shares have been down 1.8% in a while after the announcement.
The choice comes as Novo Nordisk’s proportion value has taken a battering over the last 12 months amid greater festival within the ballooning weight problems drug marketplace and disappointing trial effects for its next-generation remedies.
Chairman Helge Lund nonetheless stated the drug maker’s means stays unchanged.
“Novo Nordisk’s strategy remains unchanged, and the Board is confident in the company’s current business plans and its ability to execute on the plans,” Lund stated in a observation.
This is a breaking information tale, please take a look at again for updates.
